Related Experiment Video
Updated: Jul 1, 2026

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
Neurocognitive Function in Head and Neck Cancer Patients Prior to Radiation Therapy.
Zainab Balogun1, Fendi Obuekwe1, Catherine Bender2
1School of Medicine, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Head & Neck
|June 30, 2026
Summary
Head and neck cancer (HNC) patients showed no significant neurocognitive differences compared to healthy controls before radiotherapy. This suggests radiotherapy
Area of Science:
- Neuroscience
- Oncology
- Psychology
Background:
- Head and neck cancer (HNC) survivors often experience neurocognitive deficits.
- Understanding baseline neurocognition before treatment is crucial for assessing treatment effects.
Purpose of the Study:
- To explore neurocognitive function in HNC survivors before radiotherapy.
- To compare baseline neurocognition between HNC survivors and matched controls.
Main Methods:
- Cross-sectional, exploratory study of HNC patients (squamous cell carcinoma of oral cavity, oropharynx, larynx/hypopharynx) and matched non-cancer controls.
- Neuropsychological testing conducted prior to radiotherapy initiation.
- Matching criteria included age, sex, and years of education.
Main Results:
- No significant differences were found in baseline neurocognitive measures between HNC patients and controls.
- Specific functions assessed included attention, memory, executive function, and visuo-spatial ability.
- Results remained consistent after controlling for covariates (p ≥ 0.05).
Conclusions:
- Pre-radiotherapy neurocognitive function is comparable between HNC patients and non-cancer controls.
- Further research is necessary to investigate the long-term effects of radiotherapy on neurocognition.
- Baseline neurocognitive status may not be significantly altered by HNC itself prior to treatment.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
